

RESEARCH

Open Access



Traditional Chinese Medicine Fufang-Zhenzhu-Tiaozhi capsule prevents renal injury in diabetic minipigs with coronary heart disease

Lixia Song^{1,2†}, Ke Wang^{1,2†}, Jianying Yin^{1,2†}, Yiqi Yang^{1,2†}, Bo Li^{1,2}, Dongxing Zhang^{1,2}, Hong Wang^{1,2}, Weixuan Wang^{1,2}, Wenjing Zhan², Caijuan Guo^{1,2}, Zhanhui Gu^{1,2}, Lexun Wang^{1,2}, Zhihuan Zeng⁵, Weijian Bei^{1,2,3,4*} , Xianglu Rong^{1,2,3,4} and Jiao Guo^{1,2,3,4*}

Abstract

Background: Renal injury is one of the common microvascular complications of diabetes, known as diabetic kidney disease (DKD) seriously threatening human health. Previous research has reported that the Chinese Medicine Fufang-Zhenzhu-Tiaozhi (FTZ) capsule protected myocardia from injury in diabetic minipigs with coronary heart disease (DM-CHD). And we found significant renal injury in the minipigs. Therefore, we further investigated whether FTZ prevents renal injury of DM-CHD minipig and H₂O₂-induced oxidative injury of HK-2 cells.

Methods: DM-CHD model was established by streptozotocin injection, high fat/high-sucrose/high-cholesterol diet combined with balloon injury in the coronary artery. Blood lipid profile, fasting blood glucose (FBG), and SOD were measured with kits. The levels of blood urea nitrogen (BUN), serum creatinine (Scr), urine trace albumin (UALB), urine creatinine (UCR) (calculate UACR), cystatin (Cys-C), and β -microglobulin (β -MG) were measured by ELISA kits to evaluate renal function. TUNEL assay was performed to observe the apoptosis. qPCR was used to detect the mRNA expression levels of HO-1, NQO1, and SOD in kidney tissue. The protein expressions of Nrf2, HO-1, NQO1, Bax, Bcl-2, and Caspase 3 in the kidney tissue and HK-2 cells were detected by western blot. Meanwhile, HK-2 cells were induced by H₂O₂ to establish an oxidative stress injury model to verify the protective effect and mechanisms of FTZ.

Results: In DM-CHD minipigs, blood lipid profile and FBG were elevated significantly, and the renal function was decreased with the increase of BUN, Scr, UACR, Cys-c, and β -MG. A large number of inflammatory and apoptotic cells in the kidney were observed accompanied with lower levels of SOD, Bcl-2, Nrf2, HO-1, and NQO1, but high levels of Bax and Cleaved-caspase 3. FTZ alleviated glucose-lipid metabolic disorders and the pathological morphology of the kidney. The renal function was improved and the apoptotic cells were reduced by FTZ administration. FTZ could also enhance the levels of SOD, Nrf2, HO-1, and NQO1 proteins to promote antioxidant effect, down-regulate the

[†]Lixia Song, Ke Wang, Jianying Yin and Yiqi Yang have contributed equally to this work

*Correspondence: 13660020495@139.com; gyguoyz@163.com

⁴Institute of Chinese Medicinal Sciences, Guangdong TCM Key Laboratory Against Metabolic Diseases, Guangdong Pharmaceutical University, Guangdong, China
Full list of author information is available at the end of the article




expression of Bax and Caspase3, as well as up-regulate the expression of Bcl-2 to inhibit cell apoptosis in the kidney tissue and HK-2 cells.

Conclusions: We concluded that FTZ prevents renal injury of DM-CHD through activating anti-oxidative capacity to reduce apoptosis and inhibiting inflammation, which may be a new candidate for DKD treatment.

Keywords: Fufang-Zhenzhu-Tiaozhi (FTZ), Diabetes, Renal injury, Oxidative stress, Apoptosis

Graphical Abstract



Introduction

In recent years, with the improvement of living standards, obesity, genetic susceptibility, urbanization, and aging, the incidence of clinical diabetic kidney disease (DKD) has been rising rapidly [1]. According to statistics, there were 463 million people with diabetes mellitus (DM) worldwide in 2019. By 2045, this number will increase to 700 million [2].

The toxicity of diabetic hyperglycemia affects all organs of the body, among which the vascular system is the most affected, and it can cause a variety of microvascular complications [3–5]. Diabetes-induced renal injury is a common and serious microvascular complication in DKD, which has become the most important cause of the end-stage renal disease (ESRD), its severity is second only to cardiovascular disease [6, 7]. Although many therapeutic drugs have been developed for the treatment of DKD, such as RAAS inhibitor, SGLT2 inhibitor, antioxidant, Nrf2 activator, and NOX inhibitor, these drugs still have many deficiencies, such as increased susceptibility to genital and urinary tract infections, increased risk of heart failure, and effects are not specific [8–15]. The DKD has not been alleviated, which has increased the difficulty and economic burden of diabetes treatment [16].

Reactive oxygen species (ROS) is an important driver of diabetic complications, and the central mechanism

mediating these diabetic complications initially focuses on the dysregulation of ROS produced by mitochondria [17, 18]. Nrf2, as a key regulator of antioxidant and cell protective agent, is mainly activated in response to oxidative stress [19, 20]. Nrf2 binds to Kelch-like epichlorohydrin-associated protein 1 (KEAP-1) in the cytoplasm under physiological conditions. When the body continues to be exposed to high glucose, ROS is overproduced in the body, Nrf2 no longer binds to KEAP-1, and Nrf2 enters the nucleus and binds to antioxidant reaction elements to complete transcription and up-regulate hemoglobin oxygenase-1 (hypocretin-1) (HO-1) and Quinone oxidoreductase (NAD(P)H Quinone Dehydrogenase 1) (NQO1), thereby improving cellular oxidative stress. At the same time, excessive ROS stimulates lipid oxidation of mitochondria, destroying the structure and function of mitochondria. Apoptosis-inducing factors are released from the cytoplasm to stimulate the transport of proapoptotic proteins such as Bax and Caspase 3, thus leading to apoptosis [21, 22].

As a signal, ROS regulates the responses of multiple intracellular pathways, causing a series of reactions such as severe fibrosis, excessive oxidative stress, and severe apoptosis of kidney tissue [23]. Thus, the focus now has been on specific mechanism-based strategies that can target oxidative stress pathways to improve the outcome

of disease burden. SOD is one of the key antioxidant enzymes which could defend against ROS-induced oxidative stress in vivo [24]. Nrf2 is a redox-sensitive transcription factor, developing an important function in oxidative stress and tissue injury [20].

Metformin is an antidiabetic drug prescribed to treat type II diabetes [25]. Atorvastatin is an oral drug that is effective in lowering triglycerides, and potent in reducing LDL-C. Metformin combined with atorvastatin is an effective treatment for diabetic cardiomyopathy. However, it is limited in the treatment of DKD with its side effects [26, 27].

Fufang-Zhenzhu-Tiaozhi (FTZ), a patented Chinese herbal medicine prescription, is composed of eight traditional Chinese medicinal (TCM) herbs, including *Rhizoma coptidis*, *Radix Salvia Miltiorrhiza*, *Radix Notoginseng*, *Fructus Ligustri Lucidi*, *Herba Cirsii Japonici*, *Cortex Eucommiae*, *Fructus Citri Sarcodactylis*, and *Radix Atractylodes Macrocephala* [28, 29]. Previous studies demonstrated that FTZ has the effects of lowering blood lipid, anti-inflammatory, anti-oxidative stress, and improving insulin resistance, and has a good prevention and treatment effect on glycolipid metabolism disease [30–34]. FTZ could also protect myocardia from injury in diabetes mellitus with coronary heart disease (DM-CHD) in the minipigs model [35], and we also found that there was renal injury in the DM-CHD model. Therefore, we performed this study to explore whether FTZ has a protective effect on the complications of renal injury caused by the DM-CHD through the antioxidative signal pathway.

Methods

Materials and reagents

Test kits of glucose (GLU), triacylglycerol (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were purchased from Shanghai Rongsheng Biotech Co. Ltd. (Shanghai, China). Hematoxylin (HHS32) solution and eosin Y solution (HT110332) were purchased from Sigma-Aldrich (St. Louis, MO, USA). A periodic acid-Schiff (PAS) staining kit was purchased from Leagene Biotechnology (Beijing, China). Kits for blood urea nitrogen (BUN), serum creatinine (Scr), urine trace albumin (UALB), urine creatinine (Ucr) (calculate UACR), superoxide dismutase (SOD) kit, lactic dehydrogenase (LDH) kit, and Albumin kit were supplied by Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Cystatin (Cys-c) Elisa kit and β -microglobulin (β -MG) Elisa kit were measured by using ELISA kits according to the manufacturer's instructions (Jiangsu Feiya Biological Technology Co. Ltd., China). One-step TUNEL cell apoptosis detection kit, RIPA buffer, ROS kit, and BCA Protein Assay Kit

were purchased from Beyotime Biotechnology Co. Ltd. (Beijing, China). RNAiso Plus, Prime Script RT reagent kit with gDNA Eraser, and TB Green Premix Ex Taq II were purchased from Biomedical Technology Co., Ltd (Japan).


Antibodies against Nrf2 (ab89443), HO-1 (ab13248), NQO1 (ab2346), Bax (ab104156), Caspase3 (ab13847), Cleaved-caspase3 (ab49822) and GAPDH (ab8245) were purchased from abcam (Cambridge, UK). Antibody against β -actin (#4970 s) was purchased from Cell Signaling Technology (Beverly, MA, USA). Antibody against Bcl-2 (Bs20351r) was obtained from Bioss Biotechnology Co., Ltd. (Beijing, China).

Animals

All animal studies were conducted following the ARRIVE (Animal Research: Reporting of in Vivo Experiments) guidelines for reporting experiments involving animals. The animals were kept under monitored standard laboratory conditions, complying with the European Union guidelines (directive 2010/63/EU), and the procedures were approved by the Research Ethical Committee of Guangdong Pharmaceutical University (Guangzhou, China). Eighteen castrated male Chinese Wuzhishan minipigs were supplied by Guangdong Laboratory Animals Monitoring Institute, Guangzhou, China (Certification: SYXK Guangdong 2018–0125). Pigs weighing 9–12 kg and 11–12 weeks old were used in this study. They were housed in single pens under controlled conditions (temperature between 24 °C and 26 °C, relative air humidity 30–70%) and fed twice a day with a total daily amount of 3% of bodyweight. Filtered tap water was available randomly. Animal treatment is shown in Fig. 1.

Animal groups and treatment

After 1 week of adaptive feeding, eighteen minipigs were randomly divided into the control group ($n=4$) and the DM group ($n=14$). The DM group was developed by feeding an HFSCD and induced by STZ, while the control group received a normal diet (ND) and injected with citric acid-sodium citrate buffer. After feeding for 4 weeks, the DM group was subjected to left coronary artery interventional balloon injury surgery. After surgery, the DM group was divided into model group, FTZ group, and M + A (Metformin + Atorvastatin) group. At the following 4 to 26 weeks, the control group continued to feed with ND, while the model group, FTZ group, and M + A group continued to feed with HFSCD. The FTZ group was given 1.2 g/kg body weight of FTZ extracts (It was equal to 2 times of the clinic human dose.), administered with meals once a day. Metformin (57.08 mg/kg/d, according to the daily dose of Metformin in the clinical treatment of 2.550 g/60 kg) and Atorvastatin (0.92 mg/



kg/d, according to the daily dose in the clinical treatment of 40 mg/60 kg) were given to the M + A group minipigs. During this period, blood samples were collected from the auricular veins using heparinized tubes monthly. At the end of the experiment, the kidney tissues of pigs were collected, frozen on dry ice, and then stored at - 80 °C.

Biochemical marker determination

The plasma samples were isolated by centrifugation at 3500 rpm for 15 min at 4 °C, and the separated plasma was frozen at -80 °C for further analysis. Kits were used to determine plasma levels of GLU, TG, TC, HDL-C, and LDL-C. Biomarkers of renal function, such as BUN, Scr, Ucr, UALB, Cys-c, and β-MG were measured by the manufacturer’s instructions. Furthermore, the Urinary Albumin Creatinine Ratio (UACR, UACR = UALB/Ucr) was calculated.

Histological analysis

The kidney tissue was fixed in 4% paraformaldehyde for 36 h, dehydrated with graded alcohol, embedded in paraffin, and then sliced into 4 μm-thick sections. These sections were stained with H&E staining and PAS staining to assess histopathological changes and glycogen deposition. Sections were mounted and observed under a microscope (PerkinElmer, Vectra 3, USA).

qPCR

The kidney tissues were preserved at - 80 °C before RNA extraction. Total RNA was extracted by using the RNAiso Plus following the manufacturer’s protocol (9108, TaKaRa, Japan). cDNA synthesis was carried out with Prime Script TMRT reagent Kit with gDNA Eraser (RR047A, TaKaRa, Japan). cDNA subsequently underwent quantitative real-time polymerase chain reaction (PCR) using the sequences of the following primers:

HO-1: Forward primer (5’ → 3’): GGCATCCGACAT CCGCAAGAG,

Reverse primer (5’ → 3’): CACCTGGGAGAGGAC GCTGAG.

NQO1: Forward primer (5’ → 3’): GTGGAAGCCGCA GACCTTG TG,

Reverse primer (5’ → 3’): GCACACGTTCAAACC AGCCTTTC.

SOD: Forward primer (5’ → 3’): GAAGATTCTGTG ATGCCCTCTCG,

Reverse primer (5’ → 3’): TTCATTTCCACCTCTGCC CAAGTC.

β-actin: Forward primer (5’ → 3’): GCGACTGCGCCC CATAAAAC,

Reverse primer (5’ → 3’): ATGGCGAACTGGTAG CGGTG.

HK-2 cell-based assay

The human proximal tubular cell line HK-2 was purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in the DMEM F-12 with 10% fetal bovine serum (Gibco), 1% penicillin (Gibco), and 1% streptomycin (Gibco), under standard conditions (37°C, 5% CO₂). Cell viability was measured using Cell Counting Kit-8. Briefly, trypsin was used to digest the HK-2 cells after being grown to 90%. Moreover, the cells were seeded in the 96-well culture plate with a density of 5×10^4 cells per/well. After 24 h of cell adhesion, the culture medium was refreshed. The HK-2 cells were exposed to different concentration of H₂O₂ (0, 125, 200, 250, 500, 1000, 1500 μM) for 24 h after treatment with different concentration of FTZ (12.5, 25, 50, 100, 150, 200 μg/mL) for 1 h. Following the treatment, 10 μL CCK-8 (dark operation) was added to each well for 1 h at 37 °C. The absorbance was recorded at 450 nm with a microplate analyzer. The HK-2 cells after treatment with 200 μM of H₂O₂ and FTZ (0, 50, 100, 150 μg/mL) for 24 h were collected to further measure the levels of ROS, SOD, and LDH and the expression of related proteins with assay kits according to their manufacturer's instructions.

Western blot assay

The kidney tissues or the collected HK-2 cells were homogenized in RIPA buffer (P0013B) containing a protease inhibitor cocktail. Total protein content was quantified by using a BCA Protein Assay Kit. Membranes were incubated with primary antibodies (Nrf2, HO-1, NQO1, Bax, Caspase3, Cleaved-caspase3, Bcl-2, GAPDH, and β-actin) overnight at 4 °C, followed by incubation with secondary antibodies for 1 h at room temperature. Then, the immune-reactive protein bands were visualized with clarity using western ECL substrate purchased from Bio-Rad Company. The protein band intensity was measured by using Bio-Rad image analysis (Bio-Rad, Hercules, CA, USA).

TUNEL assay

The kidney tissues were fixed in 4% paraformaldehyde for 36 h, dehydrated with graded alcohol, embedded in paraffin, and then sliced into 4 μm-thick sections. The HK-2 cells cultured on the glass slice were also fixed with 4% paraformaldehyde. Cell apoptosis was detected using a TUNEL assay. The signal intensity of green fluorescence was observed under a fluorescence microscope.

Statistical method

All statistical analyses were performed using Graph-Pad Prism 7.0. The results were recorded as the mean ± SEM, and the differences between the groups

were analyzed by one-way ANOVA and t-test. $P < 0.05$ was considered to be a significant difference.

Results

FTZ alleviates the disorder of glucose-lipid metabolism


There was no difference between groups in the levels of GLU, TC, HDL-C, LDL-C, and TG of the minipigs at the beginning of the experiment. From 4 to 26 weeks, the levels of FBG, TC, HDL-C, LDL-C, and TG in the model group were significantly higher than in the control group. At 20 and 26 weeks, the levels of FBG, TC, LDL-C, and TG in the FTZ group were reduced significantly compared with the model group, while the HDL-C levels have no significant difference between the groups (Fig. 2). As a result, FTZ can alleviate the disorder of glucose-lipid metabolism.

FTZ alleviates renal injury in DM-CHD minipigs

We then investigated whether FTZ has a protective effect on renal injury in DM-CHD minipigs. The results of the H&E staining showed that in the model group, a large number of inflammatory cells infiltrated around the glomerulus, while no inflammatory cells were seen in the control group, and the number of inflammatory cells was decreased in the FTZ group. The results of the PAS staining demonstrated that the positive area in glomeruli and renal tubules increased significantly in the model group, indicating that there was a large amount of glycogen deposition, while it was decreased in the FTZ group and M + A group, which tended to the control group level (Fig. 3a, b). The BMI of the model group was lower than that of the control group and the kidney index of the model group was significantly higher than that of the control group. The BMI and kidney index of the FTZ group were improved and tended to be close to that of the control group (Fig. 3c, d).

The levels of BUN, Scr, Cys-C, β-MG, and UACR in plasma and urine were measured to evaluate renal function. The results showed that their levels of the model group were significantly higher than that of the control group, indicating the occurrence of renal injury. However, their levels were decreased in the FTZ group and M + A group, and the FTZ group showed better effect than the M + A group (Fig. 3e–i).

Therefore, it suggested that FTZ can alleviate renal injury in DM-CHD minipigs by improving renal function and suppressing the inflammatory and glycogen deposition pathological process.




FTZ enhances the antioxidant capacity of the DM-CHD minipigs

The level of SOD in kidney tissues was detected to evaluate the effect of FTZ on antioxidant activity in the kidney. Therefore, we further investigated the effects of FTZ on SOD levels in kidney tissue of the DM-CHD minipigs. The kidney SOD levels in the model group were significantly decreased ($P < 0.05$) compared with the control group. The kidney SOD levels in the FTZ group were

significantly increased ($P < 0.05$) compared with the model group (Fig. 4a). Meanwhile, the SOD mRNA level also has the same trend (Fig. 4d).

The protein and mRNA levels of HO-1, NQO1, and Nrf2 in the kidney tissue, which are oxidative stress regulatory factors, were detected by WB and PCR (Fig. 4b, c, e). The results showed that, in the model group, the mRNA expression of antioxidant HO-1, NQO1 and SOD was decreased, and the protein



expressions of Nrf2, HO-1, and NQO1 were down-regulated in the kidney tissues, but in the FTZ group, the mRNA expressions of antioxidant HO-1, NQO1 and SOD were increased, and the protein expressions of Nrf2, HO-1 and NQO1 were also up-regulated in the kidney tissues. And M + A group showed an inferior effect to the FTZ group.

The above results suggested that FTZ held the potential to effectively enhance the antioxidant capacity to reduce the oxidative stress response in the kidney tissues of the DM-CHD minipigs.

FTZ alleviates apoptosis of kidney tissue in DM-CHD minipigs

We further assessed the effects of FTZ on the apoptosis of the kidney of DM-CHD minipigs. As illustrated in Fig. 5a, a large number of obvious green fluorescence ($P < 0.05$) was shown in the kidney tissues of the model group compared with that of the control group. In contrast, there was little green fluorescence in the FTZ group and M + A group (Fig. 5a).

Furthermore, we further assessed the effects of FTZ on the expression of the apoptosis-related protein in the kidneys, including the pro-apoptotic factor, Bax and Caspase 3, and anti-apoptotic factor, Bcl-2. The results showed that the expression levels of Bax/Bcl-2 and Caspase 3







Fig. 4 FTZ enhances the antioxidant capacity of the DM-ChD minipigs **a** The level of SOD in the kidney tissues. **b–d** The levels of HO-1, NQO1, and SOD mRNA in the kidney tissues. **e** The expression of Nrf2, HO-1, and NQO1 protein in the kidney tissues. Values are the mean ± SEM. [#]*P* < 0.05, ^{##}*P* < 0.01 (compared to Ctrl group); ^{*}*P* < 0.05, ^{**}*P* < 0.01 (compared to Mod group) (n = 4–5)



were significantly increased, and Bcl-2 was significantly decreased in the kidneys of the model group (Fig. 5b). The expression levels of Bax/Bcl-2 and Caspase 3 were significantly decreased and the Bcl-2 was increased in the FTZ group. M + A group showed similar effects (both $P < 0.05$).


These results demonstrated that the renal injury in DM-CHD minipigs was indeed ameliorated after FTZ treatment via down-regulating the pro-apoptotic protein Bax and Caspase 3, up-regulating the anti-apoptotic factor Bcl-2, respectively.

FTZ ameliorates the cell oxidative injury induced by H₂O₂ in HK-2 cells

To establish the oxidative injury model of HK-2 cells, different concentrations of H₂O₂ were used to induce HK-2 cells’ oxidative injury. The cell viability assay with CCK-8 showed that with the concentration of H₂O₂ from 125 to 1500 μ M, the viability of HK-2 cells was

obvious decreased compared with the control group, and the viability of HK-2 cells was only about 50% when the concentration of H₂O₂ was 200 μ M (Fig. 6a). Continuously increased concentration of FTZ in the range of 0–200 μ g/mL did not cause a significant effect on the viability of HK-2 cells compared with the control group (Fig. 6b). To evaluate the effect of FTZ on oxidative stress, HK-2 cells were treated with 200 μ M H₂O₂ and gradient concentration of FTZ at 50, 100, and 150 μ g/mL.

FTZ could improve the decreasing cell viability induced by 200 μ M H₂O₂ in a concentration-dependent way. When the concentration of FTZ was 150 μ g/mL, the survival rate of HK-2 cells induced by 200 μ M H₂O₂ reached the highest and there was a significant difference compared with the FTZ 0 μ g/mL vehicle treatment (Fig. 6c). The above results showed that FTZ ameliorates the cell viability of H₂O₂-induced oxidative injury in HK-2 cells.



FTZ increases oxidative resistance and suppressed ROS production in HK-2 cells

To investigate the protective effect of FTZ on oxidative injury in HK-2 cells, the contents of ROS, SOD, and LDH in the HK-2 cells were detected by kits. Results showed that 24-h H₂O₂ treatment significantly increased the contents of ROS and LDH, but decreased SOD content, while FTZ treatment on HK-2 cells significantly decreased ROS and LDH levels (Fig. 6d, f). Meanwhile, the expression of SOD was increased with the increase of FTZ concentration compared with the model group (Fig. 6e).


FTZ protects HK-2 cells by activating Nrf2 pathway and inhibiting apoptosis

To explore the antioxidant mechanism of FTZ in HK-2 cells, the Nrf2, HO-1, and NQO1 in the HK-2 cells were further measured by western blot. As evidenced in Fig. 7a, the protein expression levels of Nrf2, HO-1, and NQO1 were notably decreased after H₂O₂ treatment

compared with the control group. Not surprisingly, the FTZ reversed the decrease of Nrf2, HO-1, and NQO1 in the H₂O₂ treated HK-2 cells, indicating that FTZ effectively activates Nrf2 pathway to increase the expression of antioxidative factor HO-1 and NQO1.

We subsequently examined the expression of apoptosis-related proteins, Bax and Bcl-2, to investigate the potent anti-apoptosis mechanism. As shown in Fig. 7b, in the model group, the expression of Bax was increased and the expression of Bcl-2 was decreased, and the ratio of Bax/Bcl-2 was significantly increased compared with that of the control group (*P* < 0.01). But FTZ decreased the expression of Bax and the ratio of Bax/Bcl-2 (*P* < 0.01), and increased the expression of Bcl-2.

These results indicate that FTZ has a protective effect on H₂O₂-induced HK-2 cell injury, and protects HK-2 cells by regulating Nrf2 to prevent oxidative stress and inhibiting the expression of apoptotic proteins, which further confirms the mechanism of action of FTZ on the kidney.



Discussion

Nowadays, renal injury, a common microvascular complication of diabetes, known as DKD, has high morbidity and mortality, which seriously threatens human health [36, 37]. It has become one of the most important causes of end-stage renal disease (ESRD) [38, 39]. Therefore, the treatment of complications of renal injury is urgent. In a lot of scientific research, TCM has been widely used to treat and control diabetes and its complications such as renal injury [40]. The FTZ is an innovative prescription with multiple targets to comprehensively prevent and cure glucolipid metabolic disease [34, 36]. FTZ effectively inhibited coronary artery incassation and protected the myocardium against injury in DM-CHD minipigs [35]. FTZ decreased proinflammatory cytokine levels and upregulated the protein expression of the PI3K/Akt pathway in the myocardium [35]. Therefore, based on our previous findings that FTZ has a protective effect on myocardial injury in DM-CHD minipigs, this paper aims

to explore whether FTZ has a therapeutic effect on renal injury complicated with DM-CHD.

In diabetes, the renal tubules are affected by a metabolic disorder, inflammation, proteinuria, hemodynamic changes, and so on. The disorder presents with persistent albuminuria and a progressive decline in the glomerular filtration rate [39]. Reliable tests for diagnosis and monitoring include urine albuminuria and the estimated GFR (eGFR) [41]. In DM-CHD minipigs, there are a large number of inflammatory cells infiltration, glycogen deposition near glomerulus and apoptotic cells in the kidney tissue, and significantly increased levels of BUN, Scr, UACR, Cys-c, and β-MG. These results demonstrated that there is a renal injury in the DM-CHD minipigs. After FTZ treatment, the levels of BUN, Scr, UACR, Cys-c, and β-MG decreased, and the pathological process was suppressed. It is suggested that FTZ can alleviate renal injury in DM-CHD minipigs.

Over the past decade, many researchers have demonstrated that oxidative stress is intricately linked and

a significant driver of these diabetic complications [42, 43]. So we detected the oxidative stress regulatory factors to explore the mechanism of FTZ prevention effect on renal injury. The results showed that the contents of SOD, HO-1 mRNA, NQO1 mRNA, and SOD mRNA in the kidney tissues were up-regulated in the FTZ group, and the protein expressions of Nrf2, HO-1, and NQO1 were significantly increased after FTZ administration. Apparently, FTZ could enhance the antioxidant capacity by activating Nrf2 pathway to relieve the oxidative stress in the kidney tissue.

Meanwhile, excessive production of ROS can lead to cell apoptosis, Caspase 3 is the prime executor of cell apoptosis and Bcl-2/Bax is the apoptosis regulator pair. Bcl-2 may block Caspase 3 to reduce cell apoptosis. Bax gene is the most important apoptotic gene. The Bax protein encoded can form a heterodimer with Bcl-2 and produce an inhibitory effect on Bcl-2 [44], so we further assessed the FTZ effect on cell apoptosis and its mechanism. We concluded that FTZ increased the expression of Bcl-2 protein and reduced the expressions of Bax and Caspase 3 protein, to alleviate apoptosis of the kidney tissue in DM-CHD minipigs. Subsequently, the role of FTZ in oxidative stress and apoptosis was verified *in vitro* with H₂O₂ induced HK-2 cellular injury. In this study, we disclosed that FTZ could elevate the expressions of Nrf2, HO-1, and NQO1 in the kidney tissues of DM-CHD minipigs and H₂O₂ induced HK-2 cells, which may directly contribute to its antioxidative effect to reduce cell apoptosis in the kidney tissues. Also, it may be owed to the enriching antioxidative compounds such as danshinone, protocatechuic acid, pinorexinol, salidroside, 5,7-dimethoxycoumarin and specnuezhenide, etc. in FTZ [29].

This study confirmed that excessive oxidative stress was one of the key pathological mechanisms of diabetic nephropathy. According to the theory of modern Chinese medicine, the product of oxidative stress is an important factor of "Zhuo" [48]. The FTZ created according to strategy "Tiao Gan Qi Shu Hua Zhuo" (modulating Gan, triggering key metabolic system to resolve pathogenic factors such as phlegm retention and dampness) has the effects of regulating lipids, lowering blood sugar, improving endothelial cell function and anti-inflammatory [29, 30, 48]. Our study demonstrated that FTZ treatment could significantly improve glucose and lipid metabolism disorders, and renal function and reduce apoptosis. FTZ also increased the protein levels of SOD, Nrf2, HO-1, and NQO1, promoted antioxidant effects, down-regulated Bax, Caspase3, and up-regulated Bcl-2 to inhibit the apoptosis of kidney tissue and HK-2 cells. These results suggest that FTZ improves the pathology and function of diabetic nephropathy by rebalancing oxidative stress, and

once again proves that regulating oxidative stress is one of the biological basis of FTZ's "Hua Zhuo".

Conclusion

In summary, our results demonstrated that FTZ can protect renal injury and improve glucolipid metabolism of DM-CHD minipigs, which are related to activating anti-oxidative stress to reduce apoptosis and inhibiting inflammation. It suggests that FTZ administration may be a promising therapeutic strategy for diabetic kidney disease.

Abbreviations

β-MG: β-Macroglobulin; BMI: Body Mass Index; BUN: Blood Urea Nitrogen; Cys-c: Cystatin; DKD: Diabetic Kidney Disease; DM: Diabetes Mellitus; DM-CHD: Diabetes Mellitus with Coronary Heart Disease; ESRD: End Stage Renal Disease; FTZ: Fufang-Zhenzhu-Tiaozhi; GFR: Glomerular Filtration Rate; GLU: Glucose; HDL-C: High Density Lipoprotein Cholesterol; HK-2: Human kidney-2; HO-1: Hypoeretin-1; Keap1: Kelch-like ECH-associated Protein 1; LDH: Lactate Dehydrogenase; LDL-C: Low Density Lipoprotein Cholesterol; MCP-1: Mono cyte chemoattractant protein-1; NQO1: NAD(P)H Quinone Dehydrogenase 1; Nrf2: Nuclear Factor Erythroid 2-Related Factor 2; RAAS: Renin-angiotensin-aldosterone System; ROS: Reactive Oxygen Species; Scr: Serum Creatinine; SGLT2: Sodium-glucose cotransporter 2; SOD: Superoxide dismutase; STZ: Streptozotocin; TC: Total Cholesterol; TG: Triglyceride; T2DM: Type 2 Diabetic Mellitus; UACR: Urinary Albumin Creatinine Ratio; UALB: Urine Micro albumin; UCR: Urine creatinine.

Acknowledgements

We thank our colleagues in Prof. JG's group for technical assistance and stimulating discussions during this investigation. Thank Wenyi Liang, Ms. Yuping Li, Mr. Yijian Huang, Mr. Jiangfeng Yu, and Ms. Wei Xu for their excellent technical help. Thank Ms. Xu Chen for her excellent English polishing in the revised manuscript.

Author contributions

LS, KW, JY, and YY contributed equally to this work. Prof. JG, Prof. XR, and Prof. WB conceptualized the study. LS interpreted the data and drafted the paper. KW and JY analyzed the data and amend this paper. YY, DZ, HW, WZ, CG, ZG, LW, and ZZ performed the experiments. YY, WB, BL, and WW reviewed and edited the work. All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by ProjektDEAL. This study was supported by grants from the National Natural Science Funds, China (No. 81530102) and the construction of the international cooperation base of Guangdong Provincial Science and Technology Department; the construction of the international cooperation base for the prevention and treatment of metabolic diseases (2016B050501003), Guangdong Provincial TCM Administration Department Grant (20151269), Basic and Applied Basic Research fund of Guangdong Province (2021A1515012553), Innovative Strong School Project of Guangdong Pharmaceutical University (2018KQNCX130), Basic and Applied Basic Research fund of Guangdong Province (2019A1515110123), The Medical Science and Technology Research Fund of Guangdong Province (A2019531). The funders had no role in study design, data collection, and analysis, manuscript preparation, or decision to publish.

Availability of data and materials

Please contact the author for data requests.

Declarations

Ethics approval and consent to participate

All animal experiments were performed following the Guide for the Care and Use of Laboratory Animals, and the procedures were approved by the Research Ethical Committee of Guangdong Pharmaceutical University.

Consent for publication

Not applicable.

Competing interests

The authors declare that there are no conflicts of interest.

Author details

¹Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Guangdong, China. ²Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong, China. ³Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), Guangdong, China. ⁴Institute of Chinese Medicinal Sciences, Guangdong TCM Key Laboratory Against Metabolic Diseases, Guangdong Pharmaceutical University, Guangdong, China. ⁵Department of Cardiovascular Diseases, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong, China.

Received: 6 April 2022 Accepted: 29 July 2022

Published online: 30 August 2022

References

- Khan MA, Hashim MJ, King J, Govender RD, Kaabi JA. Epidemiology of type 2 diabetes—global burden of disease and forecasted trends. *J Epidemiol Glob Health*. 2020;10:107–11.
- Key global findings 2021—IDF diabetes atlas tenth edition Available from: <https://diabetesatlas.org>
- Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, et al. The progress in understanding and treatment of diabetic retinopathy. *Prog Retin Eye Res*. 2016;51:156–86.
- Dehdashtian E, Mehrzadi S, Yousefi B, Hosseinzadeh A, Reiter RJ, Safa M, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. *Life Sci*. 2018;193:20–33.
- Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P, et al. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. *J Clin Invest*. 1995;96(4):1802–14.
- Varghese RT, Jialal I, Doerr C. Diabetic Nephropathy (Nursing). Treasure Island (FL): StatPearls Publishing; 2021.
- Teodoro JS, Nunes S, Rolo AP, Reis F, Palmeira CM. Therapeutic options targeting oxidative stress, mitochondrial dysfunction and inflammation to hinder the progression of vascular complications of diabetes. *Front Physiol*. 2018;9:1857.
- Roscioni SS, Heerspink HJ, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. *Nat Rev Nephrol*. 2014;10:77–87.
- Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med*. 2004;351:1952–61.
- Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. *J Am Soc Nephrol*. 2006;17:3438–46.
- Schjoedt KJ. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone. *Dan Med Bull*. 2011;58:B4265.
- Osorio H, Coronel I, Arellano A, Pacheco U, Bautista R, Franco M, et al. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. *Oxid Med Cell Longev*. 2012;2012: 542042.
- Taylor SI, Yazdi ZS, Beitelshes AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. *J Clin Invest*. 2021. <https://doi.org/10.1172/JCI142243>.
- Khoo CM, Deerochanawong C, Chan SP, Matawaran B, Sheu WH, Chan J, et al. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: an Asian perspective and expert recommendations. *Diabetes Obes Metab*. 2021;23:299–317.
- Pareek A, Chandurkar N, Naidu K. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N Engl J Med*. 2016;375:323.
- Dunachie S, Chamnan P. The double burden of diabetes and global infection in low and middle-income countries. *Trans R Soc Trop Med Hyg*. 2019;113:56–64.
- Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes*. 2005;54:1615–25.
- Santilli F, D'Ardes D, Davi G. Oxidative stress in chronic vascular disease: from prediction to prevention. *Vascul Pharmacol*. 2015;74:23–37.
- Müller SG, Jardim NS, Nogueira QCB, CW. Diphenyl diselenide regulates Nrf2/Keap-1 signaling pathway and counteracts hepatic oxidative stress induced by bisphenol a in male mice. *Environ Res*. 2018;164:280–7.
- Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. *Biochim Biophys Acta Mol Cell Res*. 2018;1865:721–33.
- Susztak K, Raff AC, Schiffer M, Böttinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. *Diabetes*. 2006;55:225–33.
- Wu Y, Chen M, Jiang J. Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. *Mitochondrion*. 2019;49:35–45.
- Patergnani S, Bouhamida E, Leo S, Pinton P, Romessi A. Mitochondrial oxidative stress and “mito-inflammation”: actors in the diseases. *Biomedicines*. 2021;9:216.
- Damiano S, Sozio C, La Rosa G, Guida B, Faraonio R, Santillo M, et al. Metabolism regulation and redox state: insight into the role of superoxide dismutase 1. *Int J Mol Sci*. 2020. <https://doi.org/10.3390/ijms21186606>.
- LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. *Endocr Rev*. 2021;42:77–96.
- Emelyanova L, Bai X, Yan Y, Bosnjak ZJ, Kress D, Warner C, et al. Biphasic effect of metformin on human cardiac energetics. *Transl Res*. 2021;229:5–23.
- Abbasi F, Lamendola C, Harris CS, Harris V, et al. Statins are associated with increased insulin resistance and secretion. *Arterioscler Thromb Vasc Biol*. 2021;41:2786–97.
- Guo J, Bei WJ, Hu YM, Tang CP, He W, Liu XB, et al. A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats. *J Ethnopharmacol*. 2011;135:299–307.
- Zhong XL, Guo J, Wang LY, Luo DS, Bei WJ, Chen YY, et al. Analysis of the constituents in rat serum after oral administration of Fufang Zhenzhu Tiaozi Capsule by UPLC-Q-TOF-MS/MS. *Chromatographia*. 2012;75:111–29.
- Chen Y, He X, Yuan X, Hong J, Bhat O, Guo J, et al. NLRP3 Inflammasome formation and activation in nonalcoholic steatohepatitis: therapeutic target for antimetabolic syndrome remedy FTZ. *Oxid Med Cell Longev*. 2018;2018:2901871.
- Li T, Zhang R, Liu Y, Yao Y, Guo J, Zeng Z. Fufang-Zhenzhu-Tiaozi capsule ameliorates rabbit's iliac artery restenosis by regulating adiponectin signaling pathway. *Biomed Pharmacother*. 2020;128: 110311.
- Bei W, Wang Y, Chen J, Zhang J, Wang L, Gu Z, et al. FTZ chinese medicine recipe protects against high-glucose-induced beta cell injury through alleviating oxidative stress. *Evid Based Complement Alternat Med*. 2019;2019:1–14.
- Hu X, Wang M, Bei W, Han Z, Guo J. The Chinese herbal medicine FTZ attenuates insulin resistance via IRS1 and PI3K in vitro and in rats with metabolic syndrome. *J Transl Med*. 2014;12:47.
- Zhang R, Li T, Guo J, Zhao Y, Liu Y, Yao Y, et al. Fufang-Zhenzhu-Tiaozi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits. *Lipids Health Dis*. 2018;17:272.
- Song L, Zhang D, Guo C, Gu Z, Wang L, Yao Y, et al. The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozi protects myocardia from injury in diabetic minipigs with coronary heart disease. *Biomed Pharmacother*. 2021;137: 111343.

36. Matsushita K. Chronic Kidney Disease Prognosis Consortium: achievements and future directions. *Nihon Jinzo Gakkai Shi.* 2015;57:1290–6.
37. Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D, et al. US renal data system 2019 annual data report: epidemiology of kidney disease in the United States. *Am J Kidney Dis.* 2020;75:A6–7.
38. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract.* 2010;87:4–14.
39. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. *Am J Kidney Dis.* 2014;64:510–33.
40. Sun GD, Li CY, Cui WP, Guo QY, Dong CQ, Zou HB, et al. Review of herbal traditional chinese medicine for the treatment of diabetic nephropathy. *J Diabetes Res.* 2016. <https://doi.org/10.1155/2016/5749857>.
41. Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ, et al. Integrating albuminuria and GFR in the assessment of diabetic nephropathy. *Nat Rev Nephrol.* 2009;5:397–406.
42. Pickering RJ, Rosado CJ, Sharma A, Buksh S, Tate M, de Haan JB. Recent novel approaches to limit oxidative stress and inflammation in diabetic complications. *Clin Transl Immunology.* 2018;7: e1016.
43. Forbes JM, Coughlan MeT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. *Diabetes.* 2008;57:1446–54.
44. Moldoveanu T, Czabotar PE. BAX, BAK, and BOK: a coming of age for the BCL-2 family effector proteins. *Cold Spring Harb Perspect Biol.* 2019;12(4): a036319.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

